| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CELL.2012.02.014 |
| P8608 | Fatcat ID | release_heemsyv7ujgi7dvrbirdwgks4y |
| P698 | PubMed publication ID | 22424220 |
| P5875 | ResearchGate publication ID | 221712654 |
| P50 | author | Annemieke Aartsma-Rus | Q42215747 |
| Pietro Spitali | Q55127026 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1085-1088 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | Splice modulating therapies for human disease | |
| P478 | volume | 148 |
| Q34464418 | A sensitive assay system to test antisense oligonucleotides for splice suppression therapy in the mouse liver. |
| Q35034350 | ALS-associated FUS mutations result in compromised FUS alternative splicing and autoregulation |
| Q35589667 | Alternative RNA splicing and cancer |
| Q26852848 | Alternative splicing for diseases, cancers, drugs, and databases |
| Q28084979 | Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy |
| Q26830637 | Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery |
| Q38290658 | Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3. |
| Q38184276 | Antisense-mediated exon skipping: taking advantage of a trick from Mother Nature to treat rare genetic diseases |
| Q34828364 | Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva |
| Q36998074 | Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating tumor suppressor p53 activity |
| Q38167681 | Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies |
| Q50999350 | Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy. |
| Q91932549 | Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates |
| Q40339014 | Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides. |
| Q42958209 | Covalent conjugation of oligonucleotides with cell-targeting ligands. |
| Q38987758 | Cytokine-induced slowing of STAT3 nuclear import; faster basal trafficking of the STAT3β isoform. |
| Q35786119 | Deciphering targeting rules of splicing modulator compounds: case of TG003. |
| Q33843195 | Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro |
| Q34001743 | Detecting and characterizing circular RNAs |
| Q42561764 | Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne Muscular Dystrophy in 2016: An Interview |
| Q45883756 | Dystrophin gene replacement and gene repair therapy for Duchenne muscular dystrophy in 2016. |
| Q47115483 | Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne. |
| Q37035750 | Exon skipping as a therapeutic strategy applied to an RYR1 mutation with pseudo-exon inclusion causing a severe core myopathy. |
| Q40625703 | Exon-skipping and mRNA decay in human liver tissue: molecular consequences of pathogenic bile salt export pump mutations |
| Q38989829 | Exploring monovalent and multivalent peptides for the inhibition of FBP21-tWW. |
| Q35027670 | Functional analysis of deep intronic SNP rs13438494 in intron 24 of PCLO gene |
| Q35327051 | Functional characterization of the spf/ash splicing variation in OTC deficiency of mice and man. |
| Q41830290 | In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2. |
| Q33807788 | LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts |
| Q28243266 | Long non-coding RNA INXS is a critical mediator of BCL-XS induced apoptosis |
| Q26775510 | MECHANISMS IN ENDOCRINOLOGY: Alternative splicing: the new frontier in diabetes research |
| Q38828951 | Managing the sequence-specificity of antisense oligonucleotides in drug discovery |
| Q36412965 | Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death |
| Q38065304 | Molecular genetics of high-risk chronic lymphocytic leukemia |
| Q86291937 | Muscular dystrophies |
| Q39233936 | Nanotherapy for Duchenne muscular dystrophy |
| Q26801582 | New approaches to the treatment of orphan genetic disorders: Mitigating molecular pathologies using chemicals |
| Q38195295 | New developments in exon skipping and splice modulation therapies for neuromuscular diseases |
| Q38725261 | Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action. |
| Q36771977 | Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). |
| Q38286217 | Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance |
| Q38698809 | Protein Sam68 regulates the alternative splicing of survivin DEx3. |
| Q28551915 | Recent advances using zebrafish animal models for muscle disease drug discovery |
| Q38310108 | Redirecting splicing with bifunctional oligonucleotides. |
| Q38865127 | Regulation of a strong F9 cryptic 5'ss by intrinsic elements and by combination of tailored U1snRNAs with antisense oligonucleotides |
| Q34460251 | Spinal Muscular Atrophy Therapeutics: Where do we Stand? |
| Q34117470 | Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model |
| Q89837706 | Splicing of enhancer-associated lincRNAs contributes to enhancer activity |
| Q37449229 | TGF-β1 Induces Polypyrimidine Tract-Binding Protein to Alter Fibroblasts Proliferation and Fibronectin Deposition in Keloid |
| Q30432053 | The alternative heart: impact of alternative splicing in heart disease |
| Q41884066 | Tissue-specific splicing of disordered segments that embed binding motifs rewires protein interaction networks |
| Q36574065 | Transcriptomic analysis of PNN- and ESRP1-regulated alternative pre-mRNA splicing in human corneal epithelial cells |
| Q92066121 | Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology |
| Q35172969 | Zinc finger protein 407 (ZFP407) regulates insulin-stimulated glucose uptake and glucose transporter 4 (Glut4) mRNA |
Search more.